Form 4: Supernus Pharmaceuticals CEO Jack Khattar Reports Changes in Beneficial Ownership

Jack Khattar, CEO of Supernus Pharmaceuticals, reports acquisition of performance share units and adjustments to his beneficial ownership of company stock.

Summary

• On February 28, 2025, Jack Khattar, the President and CEO of Supernus Pharmaceuticals, reported changes in his beneficial ownership of the company's stock.
• He acquired 35,000 Performance Share Units.
• These units vested upon achievement of individual performance objectives established on June 12, 2023.
• Following the reported transactions, Khattar directly owns 953,579 shares of common stock and indirectly owns 1,022,450 shares through the KBT Trust.
• The Performance Share Units convert to 35,000 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of performance share units and continued stock ownership by the CEO generally indicates confidence, but it's a routine filing.

Positives

• The acquisition of Performance Share Units suggests confidence in the CEO's ability to meet performance objectives.
• The vesting of performance share units indicates that performance objectives were met.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, which can be a signal of management's view on the company's prospects.

Stakeholder Impact

• The reported transactions provide shareholders with insight into the CEO's stake in the company.
• The vesting of performance share units may have a small dilutive effect on existing shareholders.

Key Dates